PGEN · Precigen, Inc.
$5.49
+0.42 (+8.28%)
At close · Jul 21
View the 10-Q filed May 13, 2026
Customer concentration
— top 4 customers 49.9% of revenue
4 customers — 49.9% of revenue (the three months ended March 31, 2025)
“For the three months ended March 31, 2025, four customers accounted for 49.9% of total condensed consolidated revenues.”
Market Cap
$1.96B
Shares
356.51M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$9.68M
+146.7%
FY2025
Net Income
-$250.64M
-98.6%
FY2025
Gross Margin
85.6%
+5.4pp
FY2017
Operating Margin
-1141.13%
+2299.1pp
FY2025
Diluted EPS
-$1.37
-191.5%
FY2025
Operating Cash Flow
-$87.83M
-28.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $18M | — | $9.68M | $3.93M | $6.23M | $26.91M | $14.27M | $31.99M | $90.72M | $151.18M | $230.98M | $190.93M | $173.61M | $71.93M | $23.76M | $13.77M | $8.01M | |
| — | $34.57M | — | — | — | — | — | — | — | — | $33.26M | $37.71M | $40.75M | $11.04M | $22K | $0 | — | |
| — | $168.41M | — | — | — | — | — | — | — | — | $197.72M | $153.22M | $132.86M | $60.9M | $23.74M | $13.77M | — | |
| — | — | — | — | — | — | — | — | — | — | 85.6% | 80.25% | 76.53% | 84.66% | 99.91% | 100% | — | |
| — | — | $41.33M | $53.07M | $48.61M | — | — | — | — | $404.59M | $143.21M | $112.14M | $147.48M | $58.98M | $48.14M | $64.03M | $70.23M | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | $33.62M | $24.9M | $18.3M | |
| — | — | $70.13M | $41.29M | $40.42M | — | — | — | — | $137.81M | $146.1M | $142.32M | $109.06M | $63.65M | $33.62M | $24.9M | — | |
| — | $1.27M | $1.27M | $3.06M | $4.85M | $4.8M | $5.27M | $5.24M | $7.92M | $11.67M | $11.47M | $15.19M | $9.87M | $4.24M | $2.88M | $3.03M | $1.26M | |
| — | — | $3.2M | $4.53M | $6.67M | $10.77M | $13.76M | $17.52M | $24.9M | $33.11M | $31.15M | $24.57M | $17.74M | $10.42M | $7.21M | $7.98M | $4.34M | |
| — | — | $120.19M | $138.95M | $105.98M | — | — | — | — | $666.18M | $368.87M | $316.09M | $320.47M | $141.89M | $81.78M | $88.93M | $90.44M | |
| — | — | -$110.51M | -$135.03M | -$99.76M | — | — | — | — | -$505.61M | -$137.89M | -$125.17M | -$146.86M | -$69.96M | -$58.02M | -$75.16M | -$82.43M | |
| — | — | -1141.13% | -3440.23% | -1602.54% | — | — | — | — | -334.45% | -59.7% | -65.56% | -84.6% | -97.26% | -244.2% | -545.64% | -1028.67% | |
| — | — | -$107.31M | -$130.5M | -$93.09M | — | — | — | — | -$472.5M | -$106.75M | -$100.59M | -$129.12M | -$59.55M | -$50.82M | -$67.17M | -$78.09M | |
| — | — | $3.87M | $6000 | $468K | — | — | — | — | $8.53M | $611K | $861K | $1.24M | $666K | $141K | $57K | $183K | |
| — | — | -$140.13M | $7M | $3.4M | — | — | — | — | -$19.02M | $22.47M | -$47.87M | $68.83M | -$10.5M | $17.72M | -$6.44M | -$2.85M | |
| — | — | — | $0 | $0 | $862K | -$3000 | -$1.18M | -$6.73M | -$11.61M | -$14.28M | -$21.12M | -$8.94M | -$5.26M | -$606K | -$274K | — | |
| — | — | -$250.64M | -$128.03M | -$96.36M | -$79.97M | -$110.97M | -$104.52M | -$171.26M | -$395.91M | -$78.37M | -$194.15M | -$86.98M | -$85.72M | -$40.91M | -$81.87M | — | |
| — | $3000 | $3000 | -$1.79M | -$458K | -$189K | -$160K | -$82K | -$930K | -$15.43M | $2.07M | -$3.88M | $1.02M | -$103K | $0 | $0 | $0 | |
| — | -$204.42M | -$250.64M | -$126.24M | -$95.9M | $28.32M | -$92.17M | -$170.52M | -$322.32M | -$509.34M | -$117.02M | -$186.61M | -$84.49M | -$81.82M | -$38.98M | -$81.87M | -$85.28M | |
| — | — | -2588.21% | -3216.18% | -1540.63% | 105.23% | -646.01% | -533.01% | -355.29% | -336.91% | -50.66% | -97.74% | -48.67% | -113.75% | -164.06% | -594.41% | -1064.27% | |
| — | — | — | — | — | — | $0 | $0 | -$1.59M | -$5.37M | -$9.8M | -$3.66M | -$3.5M | -$3.79M | -$1.93M | $0 | — | |
| — | — | -$429.64M | -$126.24M | -$95.9M | — | — | — | — | — | — | — | -$84.49M | -$81.82M | -$57.37M | -$103.87M | -$99.15M | |
| — | -$383.45M | -$429.65M | -$124.28M | -$94.36M | $24.62M | -$95.96M | -$139.06M | -$321.18M | -$522.29M | -$96.37M | -$210.06M | -$97.24M | -$81.88M | -$38.93M | -$81.87M | -$85.28M | |
| USD/shares | — | — | -$1.37 | -$0.47 | -$0.39 | $0.14 | -$0.47 | -$1.02 | -$2.09 | — | — | — | — | — | — | — | — |
| USD/shares | — | — | -$1.37 | -$0.47 | -$0.39 | $0.14 | -$0.47 | -$1.02 | -$2.09 | — | — | — | — | — | — | — | — |
| shares | — | — | 312.98M | 267.73M | 244.54M | 200.36M | 197.76M | 167.07M | 154.14M | 129.52M | 120M | 117.98M | 111.07M | 99.17M | 40.95M | 5.53M | 5.24M |
| shares | — | — | 312.98M | 267.73M | 244.54M | 200.36M | 197.76M | 167.07M | 154.14M | 129.52M | 120M | 117.98M | 111.07M | 99.17M | 40.95M | 5.53M | 5.24M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.68×
EV/EBIT
—
Biotechnology median 26.45×
P/E (TTM)
—
Biotechnology median 7.21×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Reportable Segment Aggregation Before Other Operating Segment | $9,684,000 | $3,925,000 | $6,225,000 | — | — | — | — | — |
| ActoBio | — | — | — | — | — | $3,050,000 | $134,000 | $7,524,000 |
| Biopharmaceuticals Segment | — | — | — | $14,894,000 | $922,000 | $26,577,000 | $19,167,000 | — |
| Exemplar Segment | — | — | — | $12,015,000 | $13,345,000 | $10,158,000 | $6,965,000 | — |
| Human Biotherapeutics Segment | — | — | — | — | — | $17,810,000 | $3,713,000 | $0 |
| Methane Bioconversion Platform Segment | — | — | — | — | — | — | $3,909,000 | $9,936,000 |
| PGEN Therapeutics Segment | — | — | — | — | — | $5,782,000 | $13,568,000 | $29,638,000 |
| Precigen Segment | — | — | — | — | — | — | $13,568,000 | $29,638,000 |
| Reportable Segments | — | — | — | — | — | $36,735,000 | $96,165,000 | $112,898,000 |
| Trans Ova Segment | — | — | — | — | — | $71,526,000 | $70,033,000 | $75,736,000 |
| All Other Segments | — | — | — | — | — | $10,580,000 | $4,884,000 | $30,468,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Non Us | $241,000 | $0 | $0 | $233,000 | $378,000 | $595,000 | $1,401,000 | $6,255,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|
| Product and Service | $7,866,000 | $3,925,000 | $6,150,000 | — | — | — |
| Product | $3,975,000 | $422,000 | $840,000 | — | — | — |
| Service Exemplar | $3,891,000 | $3,503,000 | $5,310,000 | — | — | — |
| Service | $3,891,000 | $3,503,000 | $5,310,000 | — | — | — |
| Papzimeos | $3,413,000 | $0 | $0 | — | — | — |
| Product Exemplar | $562,000 | $422,000 | $840,000 | — | — | — |
| Collaboration and Licensing Agreements | — | — | — | $14,059,000 | $69,540,000 | $134,624,000 |
Key facts
CIK
1356090
CUSIP
74017N105
13F (30d)
15 filings
15 filers
Visit website
Investor relations